129 related articles for article (PubMed ID: 16459177)
1. Other compounds and targets in non-small cell lung cancer.
Villaflor V; Bonomi P
Semin Oncol; 2005 Dec; 32(6 Suppl 10):S30-6. PubMed ID: 16459177
[TBL] [Abstract][Full Text] [Related]
2. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
Liu X; Yue P; Chen S; Hu L; Lonial S; Khuri FR; Sun SY
Cancer Res; 2007 May; 67(10):4981-8. PubMed ID: 17510429
[TBL] [Abstract][Full Text] [Related]
3. Proteasome inhibitors in lung cancer.
Scagliotti G
Crit Rev Oncol Hematol; 2006 Jun; 58(3):177-89. PubMed ID: 16427303
[TBL] [Abstract][Full Text] [Related]
4. [Proteasome inhibitors: induction of apoptosis as new therapeutic option in prostate cancer].
Tahmatzopoulos A; Gudegast C; Stöckle M; Wullich B; Unteregger G; Zwergel U; Zwergel T
Aktuelle Urol; 2004 Nov; 35(6):491-6. PubMed ID: 15526229
[TBL] [Abstract][Full Text] [Related]
5. CCAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction and ubiquitin/proteasome-mediated cellular FLICE-inhibitory protein down-regulation contribute to enhancement of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by dimethyl-celecoxib in human non small-cell lung cancer cells.
Chen S; Liu X; Yue P; Schönthal AH; Khuri FR; Sun SY
Mol Pharmacol; 2007 Nov; 72(5):1269-79. PubMed ID: 17684158
[TBL] [Abstract][Full Text] [Related]
6. Incorporating bortezomib into the treatment of lung cancer.
Davies AM; Lara PN; Mack PC; Gandara DR
Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4647-51. PubMed ID: 17671158
[TBL] [Abstract][Full Text] [Related]
7. Can NF-kappaB be a target for novel and efficient anti-cancer agents?
Olivier S; Robe P; Bours V
Biochem Pharmacol; 2006 Oct; 72(9):1054-68. PubMed ID: 16973133
[TBL] [Abstract][Full Text] [Related]
8. The potential role of proteasome inhibitors in the treatment of lung cancer.
Bunn PA
Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4263s-4265s. PubMed ID: 15217971
[TBL] [Abstract][Full Text] [Related]
9. [Cyclooxygenase 2 inhibitors and lung carcinoma].
Spano JP; Chouahnia K; Morère JF
Bull Cancer; 2004 May; 91 Spec No():S109-12. PubMed ID: 15239338
[TBL] [Abstract][Full Text] [Related]
10. Review article: the potential of combinational regimen with non-steroidal anti-inflammatory drugs in the chemoprevention of colorectal cancer.
Jalving M; Koornstra JJ; De Jong S; De Vries EG; Kleibeuker JH
Aliment Pharmacol Ther; 2005 Feb; 21(4):321-39. PubMed ID: 15709983
[TBL] [Abstract][Full Text] [Related]
11. TRAIL receptor targeting therapies for non-small cell lung cancer: current status and perspectives.
Stegehuis JH; de Wilt LH; de Vries EG; Groen HJ; de Jong S; Kruyt FA
Drug Resist Updat; 2010; 13(1-2):2-15. PubMed ID: 20036602
[TBL] [Abstract][Full Text] [Related]
12. New targets for non-small-cell lung cancer therapy.
Alvarez M; Roman E; Santos ES; Raez LE
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1423-37. PubMed ID: 17944567
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib sensitizes non-Hodgkin's lymphoma cells to apoptosis induced by antibodies to tumor necrosis factor related apoptosis-inducing ligand (TRAIL) receptors TRAIL-R1 and TRAIL-R2.
Smith MR; Jin F; Joshi I
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5528s-5534s. PubMed ID: 17875785
[TBL] [Abstract][Full Text] [Related]
14. Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5.
Frese S; Frese-Schaper M; Andres AC; Miescher D; Zumkehr B; Schmid RA
Cancer Res; 2006 Jun; 66(11):5867-74. PubMed ID: 16740726
[TBL] [Abstract][Full Text] [Related]
15. New targeted therapies for non-small-cell lung cancer: a focus on the epidermal growth factor receptor.
Crawford J
J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S78-86. PubMed ID: 19795580
[TBL] [Abstract][Full Text] [Related]
16. Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC.
Maione P; Gridelli C; Troiani T; Ciardiello F
Oncologist; 2006 Mar; 11(3):274-84. PubMed ID: 16549812
[TBL] [Abstract][Full Text] [Related]
17. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC.
Pennell NA; Lynch TJ
Oncologist; 2009 Apr; 14(4):399-411. PubMed ID: 19357226
[TBL] [Abstract][Full Text] [Related]
18. [Proteasome inhibitor bortezomib as an anticancer drug].
Yasui H; Hideshima T
Tanpakushitsu Kakusan Koso; 2006 Aug; 51(10 Suppl):1251-6. PubMed ID: 16922383
[No Abstract] [Full Text] [Related]
19. New developments in chemotherapy for advanced non-small cell lung cancer.
Raez LE; Lilenbaum R
Curr Opin Oncol; 2006 Mar; 18(2):156-61. PubMed ID: 16462185
[TBL] [Abstract][Full Text] [Related]
20. Use of bortezomib in B-cell non-Hodgkin's lymphoma.
Wang M; Zhou Y; Zhang L; Nguyen CA; Romaguera J
Expert Rev Anticancer Ther; 2006 Jul; 6(7):983-91. PubMed ID: 16831071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
